MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, TELA had -$5,279K decrease in cash & cash equivalents over the period. -$5,930K in free cash flow.

Cash Flow Overview

Change in Cash
-$5,279K
Free Cash flow
-$5,930K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-8,603 -21,187
Depreciation expense
153 347
Noncash interest expense
110 260
Amortization of intangible assets
95 190
Net changes in operating lease rou assets and liabilities
-375 52
Inventory excess and obsolescence charge
632 910
Stockbased compensation expense
955 2,029
Deferred income tax expense
0 85
Accounts receivable, net
107 935
Inventory
838 -610
Prepaid expenses and other current assets
-272 -14
Accounts payable
652 -448
Accrued expenses and other current and long-term liabilities
633 464
Foreign currency transaction loss
48 -83
Net cash used in operating activities
-5,719 -17,630
Purchase of property and equipment
211 146
Proceeds from the sale of product line
523 488
Net cash provided by investing activities
312 342
Proceeds from exercise of stock options
0 1
Payment of withholding taxes related to stock-based compensation to employees
21 180
Proceeds from issuance of common stock under the employee stock purchase plan
45 60
Net cash (used in) provided by financing activities
24 -119
Effect of exchange rate on cash and cash equivalents
104 -286
Net decrease in cash and cash equivalents and restricted cash
-5,279 -17,693
Cash and cash equivalents at beginning of period
52,935 -
Cash and cash equivalents at end of period
29,963 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

TELA Bio, Inc. (TELA)

TELA Bio, Inc. (TELA)